Protara Therapeutics, Inc.

NasdaqGM TARA

Protara Therapeutics, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2024

Protara Therapeutics, Inc. Cash and Short-Term Investments is NA for the quarter ending September 30, 2024. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

Protara Therapeutics, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2023 was USD 74.03 M, a -23.14% change year over year.
Protara Therapeutics, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2022 was USD 96.32 M, a 2.73% change year over year.
Protara Therapeutics, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2021 was USD 93.76 M, a -43.49% change year over year.
Protara Therapeutics, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2020 was USD 165.90 M.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

NasdaqGM: TARA

Protara Therapeutics, Inc.

CEO	Mr. Jesse Shefferman
IPO Date	Oct. 22, 2014
Location	United States
Headquarters	345 Park Avenue South
Employees	26
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.

Key trends

Past 5 years